8-K: 2seventy bio Announces Positive ODAC Vote for Abecma, Executive Departure Agreement

2seventy bio reports a positive FDA advisory committee vote for Abecma and an agreement regarding the departure of their chief scientific officer.

Summary

• 2seventy bio announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 8 to 3 in favor of Abecma, a treatment for triple-class exposed relapsed or refractory multiple myeloma.
• This positive vote is based on results from the Phase 3 KarMMa-3 study, which showed a favorable benefit/risk profile for Abecma.
• The ODAC recommendation will be considered by the FDA as they review the supplemental Biologics License Application (sBLA) for Abecma.
• The company also entered into a release and equity agreement with their chief scientific officer, Philip Gregory, who will be leaving the company upon the closing of an asset purchase agreement with Regeneron Pharmaceuticals.
• Under the agreement, Dr. Gregory's outstanding equity awards will continue to vest for 12 months after the closing in exchange for a release of claims against the company.

Sentiment

Score: 8

Explanation: The document has a positive sentiment due to the favorable ODAC vote for Abecma, which is a significant milestone. However, the departure of the chief scientific officer and the inherent risks in the pharmaceutical industry temper the overall sentiment slightly.

Positives

• The positive ODAC vote significantly increases the likelihood of FDA approval for Abecma in an earlier line of therapy for multiple myeloma.
• Abecma has already received regulatory approvals in Japan and Switzerland, and a positive opinion from the European Medicines Agency, indicating global recognition of its efficacy.
• The continued vesting of Dr. Gregory's equity awards provides him with a financial incentive during his transition.

Negatives

• The departure of the chief scientific officer could create a period of uncertainty for the company's research and development efforts.
• The release agreement with Dr. Gregory includes a release of claims against the company, which may indicate potential past issues or disputes.

Risks

• The FDA is still reviewing the sBLA for Abecma, and there is no guarantee of approval.
• The commercial success of Abecma is not guaranteed, even with regulatory approvals.
• The company faces risks related to the development and commercialization of pharmaceutical products, as well as collaboration with Bristol Myers Squibb.
• There are inherent risks and uncertainties in the pharmaceutical industry that could impact the company's future financial results.

Future Outlook

The company is awaiting the FDA's decision on the supplemental Biologics License Application for Abecma and is working to expand the benefits of Abecma to myeloma patients earlier in their treatment course. They are also focused on delivering therapies that are designed with the goal to think smarter and faster than the disease.

Management Comments

• Anne Kerber, senior vice president, head of Late Clinical Development, Hematology, Oncology and Cell Therapy, Bristol Myers Squibb, stated they are confident in the significant clinical benefit that Abecma delivers for patients with triple-class exposed relapsed or refractory multiple myeloma.
• Anna Truppel-Hartmann, senior vice president, Clinical Research and Development, 2seventy bio, said the favorable outcome of the ODAC meeting brings them another step closer to expanding the benefits of Abecma to myeloma patients earlier in their treatment course.
• Sagar Lonial, MD, FACP, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, stated that it is critical that new treatment options with the potential to improve long-term outcomes are available as early as possible.

Industry Context

The positive ODAC vote for Abecma is a significant development in the treatment of multiple myeloma, a challenging cancer with limited treatment options. The expansion of Abecma to earlier lines of therapy could potentially change the treatment paradigm for this disease. The competitive landscape includes other CAR T-cell therapies and novel treatments, but Abecma's positive results and regulatory approvals position it as a strong contender.

Comparison to Industry Standards

• Abecma's positive ODAC vote and approvals in Japan and Switzerland place it in a leading position among CAR T-cell therapies for multiple myeloma.
• The KarMMa-3 study results, which demonstrated a favorable benefit/risk profile, are comparable to or better than results seen in other similar trials for CAR T-cell therapies.
• Competitors in the multiple myeloma space include companies like Johnson & Johnson with their CAR T-cell therapy Carvykti, and other companies developing novel treatments such as bispecific antibodies and antibody-drug conjugates.
• Abecma's approval for earlier lines of therapy, if granted by the FDA, would give it a competitive advantage over other CAR T-cell therapies that are currently approved for later lines of treatment.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the favorable ODAC vote for Abecma.
• Patients with multiple myeloma may benefit from the potential expansion of Abecma to earlier lines of therapy.
• Employees may experience some uncertainty due to the departure of the chief scientific officer.
• The collaboration with Bristol Myers Squibb remains crucial for the development and commercialization of Abecma.

Next Steps

• The FDA will consider the ODAC recommendation during its ongoing review of the supplemental Biologics License Application for Abecma.
• The company will work with the FDA to complete the review of the sBLA.
• The company will continue to develop and commercialize Abecma in collaboration with Bristol Myers Squibb.
• The company will transition the responsibilities of the departing chief scientific officer.

Key Dates

Keywords

Abecma, multiple myeloma, FDA, ODAC, CAR T cell therapy, oncology, clinical trial, KarMMa-3, biologics license application, chief scientific officer, equity agreement, Regeneron Pharmaceuticals